UK markets open in 7 hours 19 minutes

Paratek Pharmaceuticals, Inc. (PRTK)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
10.23-0.20 (-1.92%)
At close: 4:00PM EDT
10.23 0.00 (0.00%)
After hours: 06:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.43
Open10.42
Bid9.50 x 800
Ask10.98 x 1300
Day's range9.90 - 10.46
52-week range4.11 - 11.24
Volume517,567
Avg. volume470,757
Market cap480.073M
Beta (5Y monthly)1.55
PE ratio (TTM)N/A
EPS (TTM)-1.92
Earnings date09 Aug 2021 - 13 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend date31 Oct 2014
1y target est18.40
  • Is Paratek Pharmaceuticals' (NASDAQ:PRTK) 151% Share Price Increase Well Justified?
    Simply Wall St.

    Is Paratek Pharmaceuticals' (NASDAQ:PRTK) 151% Share Price Increase Well Justified?

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...

  • Why Paratek Pharmaceuticals Crushed the Market Today
    Motley Fool

    Why Paratek Pharmaceuticals Crushed the Market Today

    Shares of Paratek Pharmaceuticals (NASDAQ: PRTK) flew nearly 20% higher on Tuesday, on an otherwise forgettable day for the stock market. Paratek announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (NDA) for the oral-only formulation of Nuzyra to treat adults suffering from community-acquired bacterial pneumonia (CABP), a lung disease. Previously, the FDA had approved Nuzyra in 2018 as a once-per-day oral and intravenous treatment for CABP, in addition to acute bacterial skin skin and skin structure infections (ABSSI).

  • Paratek Pharmaceuticals (PRTK) Q1 2021 Earnings Call Transcript
    Motley Fool

    Paratek Pharmaceuticals (PRTK) Q1 2021 Earnings Call Transcript

    Participants on today's call are Evan Loh, CEO; Adam Woodrow, president and chief commercial officer; Randy Brenner, chief development and regulatory officer; Michael Bigham, executive chairman; and Sarah Higgins, vice president of finance, controller, and principal accounting officer, will also be available for questions. Before I turn the call over to Evan, I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs.